Prima BioMed PE Ratio 2010-2021 | IMMP
Current and historical p/e ratio for Prima BioMed (IMMP) from 2010 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Prima BioMed PE ratio as of August 09, 2022 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Prima BioMed PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2022-08-09 |
2.23 |
|
inf |
| 2021-12-31 |
3.28 |
0 |
0.00 |
| 2017-03-31 |
2.44 |
0 |
0.00 |
| 2016-12-31 |
2.34 |
0 |
0.00 |
| 2016-06-30 |
3.23 |
0 |
0.00 |
| 2015-06-30 |
4.83 |
0 |
0.00 |
| 2014-12-31 |
2.23 |
0 |
0.00 |
| 2014-06-30 |
3.87 |
0 |
0.00 |
| 2013-12-31 |
3.67 |
0 |
0.00 |
| 2013-06-30 |
6.98 |
0 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.196B |
$0.003B |
|
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
|
